Vistagen Therapeutics ($VTGN): What Is Left of Fasedienol After PALISADE-4, and What Happens Before February 1, 2027?

01 Bull, base and bear scenarios

These are reading frames, not forecasts, and none of them is a recommendation. Each is written so that a reader can say which document would confirm or break it.

What distinguishes Vistagen from most companies at this stage is that the clinical risk has not been retired — it has been largely realised, in public, three times — and what is left is a regulatory question, a funding question and a listing question, each decided by someone other than the company. The proposed fix is one more trial, on a different primary endpoint, in a narrower population, with a 2023 trial standing as confirmatory evidence; whether that is acceptable is an FDA matter the record does not yet answer. Meanwhile the fixed points are the February 1, 2027 listing deadline, a stock that closed $0.28 on October 1 and so about 72 per cent below the $1.00 test, the June 30, 2026 cash figure of $31.7 million against a $12.54 million market value, and a funding plan stated only as seeking capital “when necessary and/or advantageous.”

What Would Falsify This Reading

The reading on this page is that the clinical question was answered badly three times out of four, that the open risks are regulatory acceptance, funding and the listing deadline, and that the safety database is the part of the asset that survives. Each of the following would damage that reading, and each is checkable.

• The failures are not ambiguous, and they are full randomised results. PALISADE-1, n=224: ANCOVA mean difference +1.6, 95% CI −3.2 to 6.4, p=0.5063. PALISADE-3: LS mean SUDS change 13.6 ±1.54 on fasedienol against 14.0 ±1.51 on placebo, with “no treatment difference… for the secondary endpoints.” PALISADE-4, n=238: −9.5 ±1.7 against −11.4 ±1.7, difference in least-squares means 1.9, p=0.427. In two of the three the placebo arm was numerically ahead. The filings do not hedge: “PALISADE-1, PALISADE-3, and PALISADE-4 did not achieve the primary and secondary endpoints.”
• The subgroup that carries the bull case is post-hoc, and it was reached after exclusions. The PALISADE-4 LSAS ≥95 analysis (n=123, difference −9.1, p=0.036) “excludes data from one site (n=15) for irregularities documented and communicated before database lock that led to site disqualification from the trial”, plus n=5 for public-speaking-challenge ceiling effects and n=1 for a placebo-run-in improvement above 20 points. The company’s own 8-K and quarterly report call the result “nominally statistically significant”; a September release called it “a statistically significant benefit.” What argues the other way, and it is the strongest counter: in the Repeat Dose Study the same LSAS ≥95 cut was prespecified, and gave p=0.05 single-dose against placebo and p=0.04 pooled — in a study whose overall primary endpoint was not significant (p=0.2).
• The safety database is real, large, and the part of the asset that survives — but the flattering numbers are uncontrolled. As of May 31, 2026: “over 1,500 subjects receiving at least a single exposure,” “over 300 subjects with at least 6-months of exposure,” “over 100 subjects with at least 12 months of exposure.” Discontinuation for adverse events ran 1.6 per cent (5 of 322) in the PALISADE-4 extension and 2.6 per cent (9 of 341) in the PALISADE-3 extension, with no serious adverse event attributed to fasedienol in either. But the extensions are open-label and uncontrolled, so the LSAS improvements of 20.2 points at month one and 31.4 at month four have no placebo arm behind them. And the company states plainly that it “has not yet aligned with the FDA on the specific patient exposure requirements to support a potential fasedienol NDA submission.”
• The February 1, 2027 deadline is mechanical, and the cure has not been decided. The requirement is a closing bid of at least $1.00 for a minimum of 10 consecutive business days during the extension period granted on August 4, 2026; failure produces written notification that the stock “will be subject to delisting, at which time the Company may appeal… to a Nasdaq Hearing Panel.” The annual report identifies the cure as implementing “a reverse stock split, if necessary” — a stated intention, not an action. No reverse split has been proposed, approved or announced, and none was on the ballot at the September 10, 2026 annual meeting. Anyone reading a reverse split as decided is reading something the record does not say. The size of the gap is now measurable rather than rhetorical: the October 1, 2026 close of $0.28 — a terminal figure — is about 72 per cent below the $1.00 threshold, a calculation, and the same screen shows a consensus price target of $1.00, reproduced here as a terminal aggregate with no individual rating, author or target published and nothing on this page built on it.
• Or the funding position is less constrained than this page implies. This is the strongest argument against the rest. There is no debt of any kind — no credit facility, no revolver, no term loan, no convertible, no royalty financing — the insurance-premium note was repaid in full by June 30, 2026, and total liabilities of $11.3 million are almost entirely payables, accruals and a $783K lease. There is $139.5 million of at-the-market capacity remaining and 217,605,705 unreserved authorised shares. Costs are falling: R&D $10.9 million in the June 2026 quarter against a programme peak of $15.9 million in the September 2025 quarter, headcount 41 full-time at March 31, 2026 from 53 full-time a year before, and R&D “expected to continue to decrease.” Against all of that, the company still concluded that “substantial doubt exists about its ability to continue as a going concern” — as it has in every periodic report since the one issued June 17, 2025 — and the market value at the October 1 close, $12.54 million on 44.38 million shares and a 44.19 million float, is about 40 per cent of the $31.7 million cash balance filed for June 30, a calculation on figures three months apart. Whichever way that gap is read, it is the figure the funding argument has to clear.

None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.

02 Executive answer: what PALISADE-4 changed

Five facts set the frame, and the first one is the correction most readers need.

The lead compound is called fasedienol. It is an intranasal pherine, administered as a nasal spray for the acute treatment of social anxiety disorder, and it is carried in the older filings under its development code PH94B. The same renaming applies across the pipeline: PH10 is itruvone and PH80 is refisolone.

On June 30, 2026 the third Phase 3 trial of fasedienol missed its primary endpoint. PALISADE-4 ran in 238 patients and measured the change from baseline in patient-rated distress on the SUDS scale during a five-minute simulated public-speaking challenge. The result in the overall population: −9.5 ±1.7 SE on fasedienol against −11.4 ±1.7 SE on placebo, a difference in least-squares means of 1.9, p=0.427 — numerically in favour of placebo. The company states that there was no treatment difference on the secondary endpoints either.

A post-hoc subgroup did separate, and the company’s own words for it moved. In patients with very severe social anxiety at baseline, defined as LSAS of 95 or above, n=123, the figures were −12.8 ±3.4 SE against −3.7 ±3.4 SE, a difference of −9.1, p=0.036. The June announcement and the quarterly report both call that “nominally statistically significant”; a release dated September 24, 2026 calls the same result “a statistically significant benefit.” It is also a filtered analysis, and the filings say so: it excludes one entire site (n=15) disqualified from the trial for documented irregularities, and six further patients to account for “public speaking challenge (PSC) ceiling and placebo effects.”

Four of the five fasedienol trials in the programme have now missed. The sentence appears verbatim in both the annual report of June 15, 2026 and the quarterly report of August 14, 2026: “PALISADE-1, PALISADE-3, and PALISADE-4 did not achieve the primary and secondary endpoints. The Repeat Dose Study… also did not achieve its primary and secondary endpoints.” The one trial that met its primary and secondary endpoints is PALISADE-2, announced in August 2023, and it was stopped early with 141 patients enrolled against a planned 208.

What PALISADE-4 changed is the development plan, not the evidence base for an application. On the day of the miss the company said it “plans to meet with the FDA to discuss a registrational pathway for fasedienol potentially supported by a single, future multi-dose Phase 3 trial with the LSAS as the primary endpoint… and confirmatory evidence from its positive PALISADE-2 Phase 3 trial.” That is a change of measuring instrument: away from the acute public-speaking SUDS score that every PALISADE trial used as its primary endpoint, and onto the LSAS, the scale on which the PALISADE-4 subgroup separated. The stated legal basis is an FDA revised draft guidance of June 2026 on demonstrating substantial evidence of effectiveness, which describes when one adequate and well-controlled trial plus confirmatory evidence can suffice.

And that meeting is the one event the record will not confirm. On August 14, 2026 the company said FDA engagement was “planned during the current quarter” and the chief executive said he looked forward to meeting the agency “in the near term”; on September 21, 2026 it repeated that it was “preparing to meet with the FDA during the current quarter.” On a calendar basis that window closed on September 30, 2026. No filing confirms the meeting took place, and no meeting type, no date for a future Phase 3 start and no application submission target exists anywhere in the record. There is no NDA on file for any Vistagen candidate, no goal date and no advisory committee scheduled or requested.

One mechanical consequence travelled with the June result. The 9,294,022 T1 Warrants at $5.380 were written to expire 60 days after the later of the PALISADE-3 and PALISADE-4 topline disclosures, so the quarterly report filed August 14, 2026 lists their expiration as August 29, 2026 — a date no later filing has yet confirmed.

03 The fasedienol programme, trial by trial

Fasedienol has been tested in social anxiety disorder in four randomised controlled trials and one exploratory repeat-dose study, alongside two open-label extensions and a terminated long-term safety study. Every controlled trial used the same primary endpoint: the least-squares mean change from baseline in patient-rated SUDS, a 0 to 100 distress scale, during a five-minute simulated public-speaking challenge. Reading the programme is a matter of holding the one positive result apart from the four that were not.

Two framing points belong with that table. The trial that worked is the smallest of the randomised set and the only one that did not run to its planned size, delivering its p=0.0153 on 141 patients against a protocol calling for 208. The two larger trials that followed it, each enrolling 238, both produced a point estimate on the wrong side of placebo. The programme’s arithmetic is therefore one positive on 141 patients against three negatives on 224, 238 and 238.

What the company has said about why they missed

The explanatory language in the record is narrow, and it is attached to PALISADE-4 rather than to the programme. The first piece is a statistical-plan change made before the readout: on May 8, 2026 the company disclosed that it had “refined the statistical analysis plan (SAP) for PALISADE-4 to incorporate each participant’s distress level immediately prior to dosing, as measured by the SUDS (pre-IP SUDS), into the primary efficacy analysis,” adding that “the FDA has informed the Company that it has no comments on the refinements to the PALISADE-4 SAP” and that no change was made to the clinical protocol. The second is the footnote to the post-hoc subgroup, which names what the company excluded data to account for: “public speaking challenge (PSC) ceiling and placebo effects” — five patients scoring above 90 on SUDS at either of two visits, and one whose score improved by more than 20 points during the placebo run-in. The third is the site disqualification, n=15.

Beyond those three items the filings do not diagnose the misses. The company’s response is expressed as a change of design rather than as an explanation: the proposed next trial would use the LSAS as its primary endpoint instead of the public-speaking SUDS. What that implies, and it is an inference, is that the company now treats the acute challenge model itself — the ceiling effect at the top of the scale and the size of the placebo response inside it — as the thing that failed, rather than the drug. The record does not say that in those words.

The open-label extensions, and what they are not

Both PALISADE extensions have reported, and both are open-label and uncontrolled, so neither bears on whether the controlled trials met their endpoints. The PALISADE-4 extension, safety population N=322 at a data cut of July 24, 2026, showed discontinuation due to adverse events of 1.6 per cent (5 of 322), none attributed to fasedienol, more than 95 per cent of events mild or moderate, headache in 18.0 per cent, upper respiratory tract infection in 9.9 per cent and no fasedienol-related serious adverse events; its LSAS series runs from a baseline mean of 99.3 (n=320) to a mean improvement of 31.4 at four months (n=197, with 65 per cent achieving at least a 20-point improvement). The PALISADE-3 extension, safety population n=341 at a cut of May 8, 2026, showed discontinuation due to adverse events of 2.6 per cent (9 of 341), with only upper respiratory tract infection at 11.4 per cent and headache at 10.9 per cent above 5 per cent.

The declining denominators are disclosed rather than inferred, and the reason is given for PALISADE-4, verbatim: “for business reasons, the Company closed the OLE portion of PALISADE-4 in July 2026, prior to the data cut. Accordingly, at the time of study closure, not all participants in the study had the opportunity to reach the four-month observation point.” An earlier open-label study, the Phase 3 Long-Term Safety Study (NCT05030350), was terminated with 481 patients started and none completed — the registry reason reads “Study stopped by the sponsor for business reasons and not due to any safety concerns with PH94B” — and its filed tally includes 9 severe treatment-emergent events and 6 serious adverse events.

Cumulative exposure, and the caveat attached to it

The safety database is the one part of the programme the company presents as complete. As of May 31, 2026 it reported “over 1,500 subjects receiving at least a single exposure,” “over 300 subjects with at least 6-months of exposure” and “over 100 subjects with at least 12 months of exposure,” exceeding, it states, the minimum recommendations of ICH E1. Its own qualification follows immediately, verbatim: “Although we believe the minimum ICH E1 recommendations have been met, we have not yet aligned with the FDA on the specific patient exposure requirements to support a potential fasedienol NDA submission.”

04 The regulatory path, and the point at which the timetable stops

The simplest way to describe Vistagen’s regulatory position is by subtraction. No new drug application has been submitted for any Vistagen product candidate. There is therefore no goal date, no decision pending in front of the agency and no advisory committee scheduled or requested for anything in the pipeline; the references to goal dates and advisory committees in the annual report are generic descriptions of the United States regulatory framework rather than statements about this company. What exists instead is a set of designations, three open investigational applications, four documented interactions with the agency, and a plan for a trial that has not started.

Designations, and the dates that are missing

Three programmes have an open United States investigational new drug application: fasedienol, itruvone and refisolone. PH15 and PH284 do not, and the company describes both as still at the stage of evaluating “the manufacturing, nonclinical and Phase 1 clinical programs required to support submission of a U.S. IND.” The newest of the three openings is refisolone’s: a “Study May Proceed” letter announced on April 22, 2026, which enables further United States Phase 2 work in vasomotor symptoms due to menopause.

The proposed path for fasedienol, and the guidance it rests on

The plan announced with the PALISADE-4 miss has been restated three times without changing shape. In the company’s words on June 30, 2026, it “plans to meet with the FDA to discuss a registrational pathway for fasedienol potentially supported by a single, future multi-dose Phase 3 trial with the LSAS as the primary endpoint… and confirmatory evidence from its positive PALISADE-2 Phase 3 trial.” The stated legal footing arrived in the same month: an FDA revised draft guidance of June 2026, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, which the quarterly report describes as setting out “certain factors FDA will consider in assessing whether one adequate and well-controlled trial plus confirmatory evidence is sufficient for demonstrating substantial evidence of effectiveness.” A draft guidance is not a commitment by the agency, and the company does not present it as one.

Two other documented interactions sit on the fasedienol file. The agency “informed the Company that it has no comments on the refinements to the PALISADE-4 SAP” in May 2026, a statement about a statistical plan rather than about evidence. And on cumulative safety exposure the company states the ICH E1 minimum has been met while adding that it has “not yet aligned with the FDA on the specific patient exposure requirements to support a potential fasedienol NDA submission.”

Every dated statement about timing, in order

That is where the timetable ends, and the list of what is absent from it is short and specific. Not in the record: any confirmation that the FDA meeting occurred, any meeting type, any date for the start of the proposed Phase 3, any enrolment target or cost for it, and any application submission target date. The company’s fiscal second quarter runs July to September, identical to the calendar quarter, so there is no reading of “the current quarter” that extends the window past September 30, 2026.

The registry says something different

The only registered dates for the three current trials are now contradicted by the company’s own disclosure. ClinicalTrials.gov still carries an estimated overall completion of October 2026 for PALISADE-3, April 2027 for PALISADE-4 and December 2026 for the Repeat Dose Study, and both PALISADE records still show status “active, not recruiting” — while the quarterly report states, verbatim, “In July 2026, we closed the open label extension portion of PALISADE-3 and PALISADE-4.” The Repeat Dose Study record is the furthest adrift: still “recruiting”, still at 60 estimated enrolment with an April 2026 estimated primary completion, eight months after topline was announced on 61 patients. Two further arithmetic problems sit in the same records: PALISADE-3 and PALISADE-4 are each registered at exactly 238 actual enrolment, yet their extension safety populations are reported as 341 and 322 respectively — more subjects in each extension than the registry says were ever enrolled in the parent trial. No results have been posted for any of the three. Where the registry and the company disagree, this page uses the company’s figures and says which is which.

The rest of the pipeline, and what the record will support

Refisolone is the one non-fasedienol programme with numbers attached. Its exploratory Phase 2a in vasomotor symptoms, run in Mexico, randomised 36 women (18 and 18) with at least eight daily hot flashes, dosed as needed up to five times a day for four weeks: hot-flash frequency fell 80 per cent on refisolone against 36 per cent on placebo, with the reduction visible as early as week 1 at p<0.001 and maintained in each treatment week; no serious drug-related adverse events. A second exploratory Phase 2a in premenstrual dysphoric disorder reports a “statistically significant improvement versus placebo” on a subject-rated daily symptom report — and no patient number, no effect size and no p-value exist in the record for it.

For the remainder, the pattern repeats: a directional claim without arithmetic. Itruvone is described as having “reduced depressive symptoms as soon as one week” on the 17-item Hamilton Depression Scale against placebo in a Mexican Phase 2a — no n, no effect size, no p-value, and no registered United States trial exists, against a stated plan to “pursue Phase 2 clinical development.” PH15 reports a statistically significant improvement in reaction time and error count against both placebo and caffeine in sleep-deprived subjects, again with no n, no effect size and no p-value. PH284 reports a cumulative effect on mean subjective feeling of hunger in female terminal-cancer patients, with a small average weight gain against a small loss on placebo — no n, no effect size, no p-value. And AV-101, the one non-pherine asset, is effectively shelved in the company’s own words: “We do not anticipate further development and commercialization of AV-101 on our own. We are currently assessing whether there is a path forward for potential third-party collaborative manufacturing, development and commercialization.” None of the Mexican Phase 2a studies conducted by the Pherin subsidiary appears in ClinicalTrials.gov at all.

05 Cash, dilution and February 1, 2027

So the headline figure, as last filed, is $31.7 million at June 30, 2026, reported in the quarterly report of August 14, 2026. Nothing more recent has been filed. The trajectory matters as much as the level: cash and marketable securities ran $80.5 million at March 31, 2025, $63.2 million three months later, back up to $77.2 million at September 30, 2025 on roughly $28.3 million of at-the-market sales inside that quarter, then $61.8 million, $45.4 million and $31.7 million. That is a fall of $31.5 million, or 49.9 per cent, in twelve months, and $13.7 million, or 30.2 per cent, in the June quarter alone.

The burn, quarter by quarter

Only the June 2025 and June 2026 quarters are reported as quarters; the four in between are arithmetic on consecutive cumulative figures in the filed statements. Three things in the table are worth holding. Operating cash use at the full-year level went from $42.1 million to $66.4 million on three concurrent fasedienol studies — $38.5 million of fiscal 2026 research spend went to the PALISADE programme alone, against $1.2 million for every other candidate combined, itself down 60 per cent year on year. The June 2026 quarter is then the lowest of the six on every line, which is what a 20 per cent workforce reduction implemented on March 5, 2026 and the conclusion of two trials look like in the accounts. And the company has told readers which way both lines go next, without a number: research expense is “expected to continue to decrease in future periods” and administrative expense “expected to remain at current levels” — both, it adds, “dependent on feedback from the FDA.” No numeric expense or cash-burn guidance has ever been given, and no year-end cash projection exists in the record.

The capital structure, in full

There is no debt. Text searches of the annual and quarterly reports return zero hits for “credit facility,” “revolving credit,” “term loan,” “indebtedness,” “convertible note” and “venture debt”; the only interest-bearing obligation of the past year was the insurance-premium note, repaid. There is no preferred stock: 10,000,000 shares authorised, none issued, and no series designated, so there are no preferred terms and no conversion rights to describe. No royalty or revenue-interest financing exists — the phrase appears only as boilerplate in a list of financing options the company might one day use.

One fact about financing history is worth stating plainly, because it bears on how the next raise would have to be done. There has been no underwritten offering, no registered direct, no private placement and no PIPE since January 1, 2024; the item in the quarterly report for unregistered sales reads “None,” and no warrant has been issued since October 2023. Every dollar raised in the past two years came through the at-the-market programme or employee plans. The last real capital-markets transaction was the October 2, 2023 offering: about $100 million gross, $93.5 million net, which is where both warrant tranches come from. Cumulatively the company has raised about $372.2 million from equity since inception against an accumulated deficit of $490.3 million.

The listing deadline: February 1, 2027

The sequence is documented in three filings and it has one date at the end of it. On February 3, 2026 Vistagen received a deficiency notice under Nasdaq Listing Rule 5550(a)(2), the minimum bid price rule, based on the closing bid price over the 30 consecutive business days from December 17, 2025 to February 2, 2026 — a window that began the day after the PALISADE-3 miss. The first 180-day compliance period ran from February 3, 2026; the same 8-K gives its end as both “August 3, 2026” and “by August 6, 2026” in two sentences, an internal inconsistency the company has not corrected. It passed uncured. Then, verbatim from the quarterly report:

“Further, on August 4, 2026, the Company received a notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC granting the Company an additional 180 calendar day compliance period, until February 1, 2027, to regain compliance with the requirement that the Company’s common stock maintain a minimum closing bid price of $1.00 per share for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2).”

Two boundaries close this out. The bid-price deficiency is the only listing-standard problem currently outstanding: no stockholders’-equity notice under Rule 5550(b)(1) and no market-value notice has been received, and equity of $24.5 million at June 30, 2026 sits far above the $2.5 million test. A separate audit-committee deficiency, self-reported on April 1, 2026 after a director’s resignation, was cured by appointing a third independent member in April 2026 — although two of the four members then left the board at the September 10, 2026 annual meeting, and no filing since confirms the committee’s composition or its continued compliance.

06 The rest of the pipeline, and what is missing from it

Behind fasedienol sit four more intranasal pherines, which arrived with the wholly owned subsidiary Pherin Pharmaceuticals, Inc., acquired in February 2023, plus one orphaned oral asset. The pattern across every candidate behind the lead is the same: the clinical signals are described in words, and the numbers behind them are, with one exception, absent from the record. Every supporting Phase 2a study was run in Mexico by Pherin and none appears in ClinicalTrials.gov.

One negative result in the lead molecule’s own family belongs here rather than in the PALISADE section, because of where it is filed. PH94B was tested in adjustment disorder with anxiety in a Phase 2a, n=41 (19 active, 22 placebo), and it missed outright: the primary Hamilton Anxiety endpoint gave a least-squares mean change of −12.5 ±1.31 against −12.6 ±1.22, a difference of 0.1, 95 per cent confidence interval −3.5 to 3.8, p=0.9338, posted to the registry on February 5, 2026. The point is the filing location: the annual report for the year to March 31, 2026 and the following quarterly report contain zero mentions of “adjustment disorder.” The result is public and in the registry and is not in the periodic filings reviewed — an observation about disclosure practice rather than about the drug, and offered as one.

Finally, who pays for any of it. One partnership is live and it does not touch the rest of the pipeline. The June 2020 licence and collaboration agreement with AffaMed Therapeutics covers fasedienol only, in Greater China, South Korea and five Southeast Asian markets, with United States and rest-of-world rights retained. The terms: a $5.0 million upfront paid August 2020, milestones of up to $172.0 million, and royalties for the later of ten years or the expiry of market or regulatory exclusivity. Termination rights, change-of-control provisions and diligence triggers are not disclosed in either the annual or the quarterly report. The other arrangement has gone: the Fuji Pharma exclusive negotiation over refisolone in Japan, signed September 1, 2023 for a non-refundable $1.5 million received in November 2023, expired during the June 2026 quarter without a definitive licence, and the company “expects no further revenue” under it. No other partnership, licence or collaboration is disclosed, no in-licence royalty is payable, and cumulative government grants since inception total $22.7 million with no current award disclosed. So: four unregistered Phase 2a signals, one of them quantified, two without a United States IND, one shelved oral asset looking for a partner, and no outside money funding any of it.

07 Register, insiders, and a short position on collapsing volume

The register: two holders above five per cent, and a proxy that says there are none

No Schedule 13D or 13D/A has ever been filed against this company. There is no activist and no control-intent filer; every beneficial-ownership filing is passive. What they show is a register that turned over almost completely in the year to June 2026.

Two ownership percentages from the same terminal screen belong here, kept apart from the proxy figure above so that the three are not conflated. The terminal, read on October 2, 2026, gives insider ownership of 0.42 per cent and institutional ownership of 26.94 per cent against a 44.38 million share count. Neither is the proxy’s 2.93 per cent: that figure is the proxy’s own beneficial-ownership count for eleven named directors and executive officers at the July 22, 2026 record date, while these are vendor screen aggregates at the October 1, 2026 close on the vendor’s own basis. Different dates, different bases: neither replaces the other and they should not be added. The institutional figure in particular cannot be tied line by line to the register above, where every entry below five per cent carries a December 31, 2025 event date and one of them consists of warrant shares.

Insiders: no purchases, no sales, and no plan on any filing

Across eighteen months, twenty-seven Form 4s and five Form 3s: not a single open-market purchase, zero transactions coded P by any officer or director; not a single sale or disposition of any kind, and no tax-withholding transaction or withholding footnote anywhere; not a single option exercise, consistent with $0 aggregate intrinsic value on the option pool at every measurement date; every reported transaction an acquisition, either an option grant or an employee-plan purchase. And the Rule 10b5-1 box is not checked on any of the twenty-seven filings: every periodic report back to the year ended March 2025 states that no director or officer adopted or terminated a pre-arranged plan, so there are no plan adoption dates to report because there are no plans. What the grant record shows is the price falling through its own strike prices, then a retention round struck underneath all of them.

Options outstanding stood at 5,249,249 at a weighted average exercise price of $6.33 at June 30, 2026, with 2,560,518 exercisable at $10.91 and $0 intrinsic value on every line; no restricted or performance share units are outstanding at all. The employee purchase plan is the only place insiders put their own cash in, and the price says where the stock was: on June 30, 2026 the chief executive bought 36,818 shares at $0.1921, described on the filing as “the maximum amount permitted under the ESPP,” taking his direct holding to 54,846 alongside 20,875 in a family trust; the chief legal officer bought the same 36,818 at $0.1921, also the stated maximum; the chief financial officer bought 11,712. The plan price is 85 per cent of the lower of two reference dates, so $0.1921 implies a reference market price of about $0.226, a calculation; the two earlier periods ran at $1.70 and $0.5626. These are discounted plan purchases, not open-market conviction.

Management and the board, as the proxy gives them

Six executive officers were listed at June 15, 2026: Shawn K. Singh, J.D., 63, President and Chief Executive Officer and a director — chief executive and director since August 2009, president since December 2024; Nick B. Tressler, MBA, 53, Chief Financial Officer and Treasurer since December 2025; Reid G. Adler, J.D., 72, Chief Legal Officer since May 2022; Angel S. Angelov, M.D., MBA, 57, Chief Medical Officer since May 2026; Elissa S. Cote, 51, Chief Corporate Development Officer since June 2025, a title the proxy renders as “Chief Corporate Development and Strategy Officer”; and Joshua S. Prince, MBA, 55, Chief Operating Officer since October 2023. Only the chief executive has an employment agreement, on a $650,000 base salary effective October 2023 with a bonus opportunity of up to 50 per cent; the others hold offer letters, and no cash bonus was paid to the chief executive, the chief legal officer or the chief operating officer for the year to March 31, 2026.

The turnover underneath is the story. The chief financial officer resigned September 10, 2025, effective October 15, 2025, the filing stating her decision “is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.” On November 12, 2025 the chief executive was appointed to act, on a temporary basis, as interim principal financial and accounting officer — disclosed in a quarterly report rather than on a current report — with the permanent appointment following on December 1, 2025 at $450,000 plus a $50,000 signing bonus. On the board, a director appointed in October 2025 resigned February 13, 2026, 109 days later, with no reason given; a second resigned effective April 1, 2026, also with no reason given, cutting the audit committee from three members to two and triggering a self-reported listing deficiency; and two more declined to stand for re-election in June 2026.

Headcount is down with the spend: 41 full-time employees at March 31, 2026 — 30 in research and laboratory support, 11 in management, corporate development and communications, legal, human resources and other administration — against 53 full-time and 2 part-time a year earlier and 56 and 1 at May 31, 2025. The step down came from a board-approved reduction in force of approximately 20 per cent implemented March 5, 2026, intended “to provide disciplined cash management while prioritizing efficient execution of ongoing clinical studies.” No dollar charge is disclosed; the annual report confirmed the costs “were not material,” and accrued employee compensation fell from $3,360 thousand to $323 thousand over the year. No second restructuring has been announced, and no headcount figure exists for any date after March 31, 2026. Controls were concluded effective at both March 31 and June 30, 2026, with no material weaknesses and no disagreements with the auditors.

Litigation: five actions, four of them pending, and no accrual anywhere

The filings do not say there is no litigation; they say the opposite, at length, and a commitments and contingencies note exists cross-referencing every matter. No loss accrual, no reasonably-possible loss range and no insurance-recovery estimate is given for any of them. Verbatim: “The Company believes all allegations in these legal proceedings are wholly without merit, and intends to vigorously defend itself.”

• A securities action brought pro se in the Northern District of California on February 13, 2025 — DISMISSED WITH PREJUDICE on August 12, 2026. Two individuals sued the company, its board, certain officers, its advisors and industry analysts over alleged misleading statements and omissions about clinical trials, under Section 10(b) and Rule 10b-5 and Sections 11 and 17(a). No appeal is mentioned.
• A derivative action in the District of Nevada, filed pro se April 10, 2026 by the same plaintiffs — PENDING on allegations “primarily the same.” On July 29, 2026 the company moved for a $100,000 bond under Nevada Revised Statutes §41.520 before the plaintiffs may proceed. The outcome of that motion is not in the record.
• A putative securities class action in the Northern District of California, filed January 15, 2026 against the company, the chief executive and the chief operating officer — PENDING, alleging false and misleading statements and concealment of material adverse facts concerning the PALISADE-3 Phase 3 trial under Sections 10(b) and 20(a) and Rule 10b-5. Lead plaintiff appointed April 16, 2026, amended complaint June 16, 2026, and a class period from April 1, 2024 to December 16, 2025, both dates inclusive — ending the day before the PALISADE-3 topline. Damages unspecified. The company “is obligated to respond by August 18, 2026”; whether that response was filed, and any ruling, is not in the record.
• Two further derivative actions, filed March 26 and May 13, 2026 — CONSOLIDATED AND STAYED pending resolution of the class action, by an order of July 30, 2026.

One inconsistency inside that disclosure reads as a drafting error rather than a dispute: the contingencies note calls the dismissed California case “recently dismissed by the Court, with prejudice,” while the legal proceedings section of the same filing still says the company “intends to defend them vigorously.” Separately, no strategic review has been announced, no financial adviser engaged or named, no takeover interest, approach, letter of intent or acquisition proposal disclosed, and there is no stockholder rights plan — searches of the annual report, the quarterly report and the August earnings release return zero hits for each of those terms. The only language in that territory is self-directed: the chief executive on having moved to “evaluate strategic options, and preserve cash.”

The short position, and the volume underneath it

Read strictly off the data: the series high of 3,385,220 shares falls on the December 31, 2025 settlement — the first after the PALISADE-3 miss of December 17 — alongside volume of 10,198,793, one of two extreme outliers against a normal range of roughly 0.4 to 1.3 million; the other is 13,056,772 on August 14, 2026. Short interest bottomed at 1,410,489 on March 31, 2026 and has risen 69.9 per cent from there and 27.3 per cent from the October 15, 2025 reading, to 2,707,020 at September 15, 2026 — 6.10 per cent of the 44,376,911 shares outstanding at August 10, 2026, a calculation. On a terminal screen read on October 2 the same position is 6.13 per cent of a 44.19 million float, which is what 2,707,020 shares against that float works out to: the exchange series and the terminal agree here to two decimal places, and the float figure is corroborated by the arithmetic rather than taken on trust.

The interesting column is the last one. 7.644 days to cover is the highest reading in the twelve-month series, and it is not mainly a function of the position growing. Short interest rose about 27 per cent over the year; the denominator, average daily volume, fell to 354,148, the lowest in the series. What the figure describes is a liquidity collapse at least as much as a short build: the same position takes three times as long to cover because far fewer shares change hands. That is a reading of the arithmetic, not a claim about intent. One basis conflict belongs on the record rather than buried in it: the exchange computes that column on an average daily volume of 354,148 for the September 15 settlement period, while the terminal screen read on October 2 gives an three-month average volume of 12,677,950, a session volume of 2,030,982 and. The two averages are measured over different windows and are not interchangeable; the days-to-cover column above is the exchange’s, on the exchange’s denominator. The relative-volume reading is reproduced as a terminal figure and nothing further is read into it. The latest published settlement is September 15, 2026, a seventeen-day lag; the September 30 settlement has not yet been published.

Analyst coverage

One consensus figure is worth printing with its provenance attached. A paid market-data terminal, read on October 2, 2026, shows a consensus price target of $1.00 against the $0.28 close of October 1, 2026, with the same screen giving a float of 44.19 million shares, insider ownership of 0.42 per cent, institutional ownership of 26.94 per cent and short interest at 6.13 per cent of float — the last of which reconciles with the 2,707,020 shares published by the exchange at the September 15 settlement and corroborates the float figure. The consensus target of $1.00 is the same number as the Nasdaq minimum bid price requirement of $1.00 a share; the two are recorded here side by side, without further comment. What this page does not publish is any individual rating, author or target, because no single rating action on this company is traceable to a named primary or first-tier publication — the only appearance of the word “analysts” in the periodic filings is the recital of the dismissed securities complaint, which named industry analysts among the defendants. The consensus is reproduced as a terminal aggregate, with that label on it, and nothing on this page is built on it.

08 Catalyst map, red flags and the Merlintrader bottom line

The catalyst map

The nearest dated item in the record is not a clinical one. It is a listing deadline, and it is fixed by exchange rule rather than by anything the company controls. Behind it the clinical calendar is empty: there is no application on file with the FDA, no goal date, no decision pending and no advisory committee scheduled or requested for any Vistagen candidate, and no date has been given for the start of the trial the company says it wants to run.

Red flags

• The listing deadline of February 1, 2027 is the nearest dated item and the hardest. At the $0.28 close of October 1, 2026, a terminal figure, the stock is about 72 per cent below the $1.00 minimum bid — a calculation — with four months to the deadline. The deficiency notice came on February 3, 2026, on a 30-business-day failure window running December 17, 2025 through February 2, 2026 — which began the day after the PALISADE-3 topline. The first compliance period ran to August; a second was granted to February 1, 2027, and the cure requires a $1.00 closing bid for ten consecutive business days. The annual report records that obtaining the second period required telling Nasdaq the company intended to cure “by implementing a reverse stock split, if necessary.” No reverse stock split has been proposed, approved or announced, and no such proposal was put to the September 10, 2026 annual meeting. One reverse split exists in the company’s history — a stockholder-approved one-for-thirty implemented June 6, 2023.
• Substantial doubt about the ability to continue as a going concern, concluded in the June-quarter filing and disclosed in every periodic report reviewed back to June 2025: $31.7 million of cash and marketable securities at June 30, 2026, $14.7 million of operating cash use in that quarter alone, and an accumulated deficit of $490.3 million. Against the filed figures, the terminal puts market value at $12.54 million at the October 1 close — below the June-quarter cash position of $31.7 million and below the $24.5 million of book equity, stated as the comparison it is.
• Three of the four PALISADE Phase 3 trials missed their primary endpoint. The company’s own words: “PALISADE-1, PALISADE-3, and PALISADE-4 did not achieve the primary and secondary endpoints.” PALISADE-3 gave a least-squares mean SUDS change of 13.6 ±1.54 on fasedienol against 14.0 ±1.51 on placebo, with “no treatment difference… for the secondary endpoints.” PALISADE-4, n=238, gave −9.5 ±1.7 against −11.4 ±1.7, a difference in least-squares means of 1.9, p=0.427. PALISADE-1, n=224, gave a mean difference of +1.6, 95 per cent confidence interval −3.2 to 6.4, p=0.5063.
• The one positive Phase 3 was stopped early. PALISADE-2 met its primary and secondary endpoints — difference −5.8, 95 per cent confidence interval −10.5 to −1.1, p=0.0153 — on 141 patients enrolled of a planned 208.
• The proposed path forward rests on a post-hoc subgroup with exclusions. The PALISADE-4 very-severe subgroup (baseline LSAS at or above 95, n=123) gave −12.8 ±3.4 against −3.7 ±3.4, difference −9.1, p=0.036, which the current report and the June release both call “nominally statistically significant” while a September press release called it “a statistically significant benefit.” The subgroup excludes one site (n=15) disqualified for “irregularities documented and communicated before database lock,” plus a further n=5 and n=1 excluded for ceiling and placebo-run-in effects.
• The exploratory Repeat Dose Study also did not achieve its primary or secondary endpoints — N=61, primary not statistically significant (p=0.2) — though it met its safety objective, and its prespecified very-severe subgroup reached p=0.05 single-dose and p=0.04 pooled.
• Dilution is the defining financial fact. The share count rose 53.0 per cent in twelve months, from 29,286,585 at June 30, 2025 to 44,381,433 at June 30, 2026. The at-the-market programme with Jefferies, dated May 14, 2021 and raised to $175 million of capacity in June 2025 at a commission of “up to three percent,” sold 10,403,244 shares for $30.6 million net in the year to March 2026, then 1,580,176 shares for $928 thousand in the June quarter — and 1,412,136 shares for about $833,000 between April 1 and June 12, 2026 at a weighted average of $0.6052, the only average price the company has disclosed. About $139.5 million of capacity remained at June 30, 2026, against 325,000,000 authorised common shares and 217,605,705 unreserved.
• The instruments behind that count: the last capital-markets transaction was the October 2, 2023 public offering — about $100 million gross, $93.5 million net, 15,010,810 shares plus 3,577,240 pre-funded warrants, each carrying a ratable portion of T1 Warrants (9,294,022 at $5.38) and T2 Warrants (11,265,086 at $8.877). The remaining 2,788,620 pre-funded warrants at $0.001 were all exercised in June 2026. There has been no underwritten offering, registered direct, PIPE or private placement since January 1, 2024.
• Not one insider has bought a share on the open market in eighteen months, through two Phase 3 misses; every Form 4 transaction is an acquisition by grant or employee plan, and no Rule 10b5-1 plan has ever been adopted. Officer and director grants in April, May and July 2026 struck at $0.5358, $0.5955 and $0.2433; aggregate option intrinsic value is $0 at every measurement date.
• The register emptied out. A holder reporting 13.6 per cent in August 2025 reported zero four months later; another exited 3,060,000 shares entirely; a third sold its whole common position; a fourth cut 38.7 per cent. And the July 31, 2026 proxy reports no five-per-cent holder at all, while two filings two weeks later report 9.9 and 5.1 per cent.
• Four securities and derivative actions remain pending, with no accrual, no reasonably-possible loss range and no insurance-recovery estimate disclosed for any of them. One class action names the chief executive and the chief operating officer and runs a class period that ends the day before the PALISADE-3 topline.
• Governance dissent escalated sharply. Withheld votes against the chief executive went from about 3.4 per cent in 2025 to 41.5 per cent in 2026, and say-on-pay opposition from 2.5 to 14.7 per cent. The board is down to four directors, and no filing confirms audit-committee compliance after September 10, 2026.
• The pipeline behind fasedienol is unfunded and unquantified. Research spending on all non-fasedienol candidates fell 60 per cent to $1.2 million; four programmes have no n, no effect size and no p-value in the record and no registry entry; two have no United States IND; AV-101 is explicitly not being developed by the company.
• A negative Phase 2a in adjustment disorder (p=0.9338), posted to the registry February 5, 2026, appears nowhere in the periodic filings reviewed. Nor have results from PALISADE-3, PALISADE-4 or the Repeat Dose Study ever been posted to ClinicalTrials.gov, and the Repeat Dose record still reads “RECRUITING” with 60 estimated enrolment eight months after topline at N=61.
• The registry and the company disagree on arithmetic. PALISADE-3 and PALISADE-4 are each registered at exactly 238 actual enrolment, yet their extension safety populations are reported as 341 and 322 — more subjects in the extension than the registry says were ever enrolled, unexplained.
• The exposure base for a future application is not agreed with the regulator. The company reports “over 1,500 subjects” with at least one exposure as of May 31, 2026, and then states plainly: “we have not yet aligned with the FDA on the specific patient exposure requirements to support a potential fasedienol NDA submission.”
• Document quality is uneven. One current report gives two different end dates for the first compliance period (“August 3” and “by August 6, 2026”); another describes the shelf registration as filed in February 2025 and declared effective in February 2024; a contingencies note calls a case dismissed while the same filing says it will be defended; prior-year full-year revenue falls below that year’s nine-month figure, implying an unexplained −$15 thousand quarter; and one officer’s Form 4 footnote carries another officer’s vesting-start date.

What to watch, in order

1. The closing bid price, and whether a reverse split is proposed. This is the binary on the file. A $1.00 bid for ten consecutive business days before February 1, 2027 cures it; failing that, the company told Nasdaq it would implement a reverse split “if necessary,” and no such proposal exists yet.
2. Whether the FDA meeting happened, and what came out of it. The company set its own window twice and it closed on September 30, 2026 with nothing filed. The subject is a single new multi-dose Phase 3 with the LSAS as primary endpoint, supported by PALISADE-2 and by the June 2026 draft guidance on substantial evidence of effectiveness.
3. The September-quarter report. Cash against the $31.7 million starting point and the $14.7 million quarterly burn; whether research expense fell as guided and administrative expense held; the restated warrant count; and the severance plan exhibit.
4. How hard the at-the-market line is used at these prices. It raised $928 thousand in the June quarter at an implied net under $0.60 a share. With $139.5 million of capacity against 44.4 million shares, the financing line is the most direct read on how the deadline is being managed.
5. Any open-market insider purchase. There has not been one in eighteen months, and with a June employee-plan reference price near $0.226 and a $0.28 close on October 1, 2026, its absence is itself information.
6. The two open court items — whether the company’s August 18 response was filed in the class action and how it was received, and whether the $100,000 bond was ordered in the Nevada derivative action.
7. Audit committee composition. Two members left at the annual meeting and the newest director had no committee seats in the proxy. A filing naming the committee would close the gap.
8. Whether refisolone gets funded. It is the only non-lead programme with a quantified controlled result and an FDA “Study May Proceed” letter, and the Japanese negotiation over it lapsed without a licence. A started United States Phase 2 would mean a second shot on goal; silence means cash preservation won.
9. Any partnership at all. The funding plan names three sources — equity and debt sales, non-dilutive grants, and “non-dilutive strategic partnering collaborations” — and only the first has produced anything since 2020.
10. Short interest and liquidity together. Days to cover reached 7.644 on the lowest average daily volume in the series; whether the next settlements show the position growing or the volume returning tells you which is driving it.

Merlintrader bottom line

The useful way to read Vistagen is that the clinical argument it was built to win has been run four times and lost three of them, and the one it won was stopped early. PALISADE-1, PALISADE-3 and PALISADE-4 all missed the primary endpoint, in the company’s own words; PALISADE-2 met it on 141 patients of a planned 208. The exploratory Repeat Dose Study missed too, at N=61 and p=0.2. What survives as a forward plan is a single new multi-dose Phase 3 with the LSAS as the primary endpoint, resting on a post-hoc very-severe subgroup that the company itself calls nominally significant and that excludes a disqualified site, plus confirmatory evidence from the one positive trial, plus a draft FDA guidance published in June 2026. The company has said twice that it is preparing to meet the agency about it. That window closed on September 30, 2026 with no confirmation on the record.

Where the open-label data is genuinely reassuring is on safety, and that should be stated as flatly as the misses. Across 341 subjects in the PALISADE-3 extension and 322 in the PALISADE-4 extension, discontinuation for adverse events ran 2.6 and 1.6 per cent, none attributed to fasedienol, more than 95 per cent of events were mild or moderate, and there were no fasedienol-related serious adverse events. The open-label symptom numbers are large — a 31.4-point mean LSAS improvement by month four in PALISADE-4, with 65 per cent improving by twenty points or more — but they come from an uncontrolled study closed early “for business reasons” before all participants reached that point.

The financial position is simpler and more pressing. $31.7 million of cash and marketable securities at June 30, 2026, down from $45.4 million three months earlier and $63.2 million a year earlier; $14.7 million of operating cash use in the quarter; substantial doubt about going-concern status, disclosed in every periodic report reviewed since June 2025. The terminal puts market value at $12.54 million at the $0.28 close of October 1, 2026, on 44.38 million shares and a 44.19 million float — below both the June-quarter cash position and the $24.5 million of book equity. Against that, the balance sheet is unusually clean: no debt of any kind — no credit facility, no term loan, no convertible, no royalty financing — the only interest-bearing obligation, an insurance-premium note, repaid in full; no preferred issued and no series designated; total liabilities of $11.3 million, almost all payables, accruals and a lease; and equity of $24.5 million, above the exchange’s equity standard, so the bid price is the only listing test in play. Revenue of $1,476 thousand in the June quarter is not a commercial event: it is the release of the remaining $1.3 million of deferred revenue from the lapsed Japanese negotiation, and the company “expects no further revenue” from it.

The funding mechanics are where the deadline and the dilution meet. The only instrument that has produced cash since 2020 is the at-the-market line, and it has produced it by issuing shares into a falling price: 10,403,244 shares for $30.6 million net in the year to March 2026, then 1,412,136 shares for about $833,000 at a weighted average of $0.6052 in the spring, then 1,580,176 for $928 thousand in the June quarter. The share count is up 53.0 per cent in twelve months; $139.5 million of programme capacity remains, against 325,000,000 authorised shares. Cost has been cut to match — a 20 per cent reduction in force in March 2026, headcount at 41, no bonuses paid, research expense guided down — but no numeric expense or cash-burn guidance has been given in any period, so the runway statement is the only quantity on offer, and in August it was narrowed to cash “not expected to be sufficient to extend the Company’s cash runway for more than a year from now.”

So the file resolves into four questions, none of which requires a view on psychiatry. Does the bid price recover to $1.00 for ten consecutive business days before February 1, 2027 — from $0.28, about 72 per cent below it — or does a reverse split proposal appear? Did the FDA meeting happen, and does a registrational path emerge from it? What does the September quarter show on cash and on burn? And who funds the next trial — an at-the-market line at well under a dollar, a partner that does not yet exist, or neither? Three of the four answers are due in documents inside the next four months. On the other side of the ledger sits a company with no debt, no preferred, positive equity, a safety database of more than 1,500 exposed subjects, five pherines, four Fast Track designations and an accumulated deficit of $490.3 million behind it — which is the full set of what a reader has to weigh, in both directions.

None of the above is a recommendation, a target, or a view on the share price. It is a description of what is documented, what is guided, what is calculated and labelled as such, and what the record does not say.